Literature DB >> 30829265

A comparative analysis of quality of life after postoperative intensity-modulated radiotherapy or three-dimensional conformal radiotherapy for cervical cancer.

Sarthak Kumar Mohanty1, Supriya Chopra1, Anisha Mudaliar2, Sadhana Kannan3, Umesh Mahantshetty2, Reena Engineer2, Jaya Ghosh4, Jyoti Bajpai4, Sudeep Gupta4, Shyamkishore Shrivastava2.   

Abstract

AIMS: The aim of this study is to compare the quality of life (QOL) between adjuvant three-dimensional conformal radiotherapy (3DCRT) or intensity-modulated radiotherapy (IMRT) for cervical cancer.
MATERIALS AND METHODS: QOL assessment was done at the baseline and then longitudinally after completing (chemo) radiation. All patients completed EORTC QLQ-C30 and EORTC QLQ Cx-24 modules. Independent-sample t-test was used to compare the mean scores between the two groups. Analysis of variance was used to compare differences in QOL measures over the six time points (baseline, post-RT, 3, 6, 9, and 12 months after treatment) and between treatment groups (3DCRT vs. IMRT). Linear mixed model was also performed to account for attrition.
RESULTS: Overall, 64 patients (image-guided IMRT, n = 40 and 3DCRT, n = 24) completed QOL assessment. The median age and follow-up period were 48 years and 15.5 months, respectively. General QOL domains such as emotional (at 12 months, P = 0.04) and social (at 3 months, P = 0.02 and 12 months, P = 0.03) were better with IMRT. Pain (12 months, P = 0.03); fatigue (12 months, P = 0.05); nausea and vomiting (12 months, P = 0.03); insomnia (post-RT, P = 0.05 and 12 months, P = 0.03); appetite loss (post-RT and 12 months, P = 0.04); and diarrhea (6 months, P = 0.02 and 12 months, P = 0.003) scores were significantly better with IMRT. On linear mixed model analysis, there was a significant interaction between treatment cohort and assessment intervals for physical, emotional, and social functioning, appetite loss, diarrhea, lymphedema, and menopausal symptom scores were significantly better with IMRT.
CONCLUSIONS: Treatment technique (IMRT vs. 3DCRT) impacts early QOL in undergoing adjuvant radiation for cervical cancer.

Entities:  

Keywords:  Cervical cancer; intensity-modulated radiotherapy; quality of life; three-dimensional conformal radiotherapy

Mesh:

Year:  2018        PMID: 30829265     DOI: 10.4103/ijc.IJC_453_17

Source DB:  PubMed          Journal:  Indian J Cancer        ISSN: 0019-509X            Impact factor:   1.224


  5 in total

Review 1.  Lower extremity lymphedema in patients with gynecologic malignancies.

Authors:  Kimberly Dessources; Emeline Aviki; Mario M Leitao
Journal:  Int J Gynecol Cancer       Date:  2020-01-07       Impact factor: 3.437

2.  Effects of high-quality nursing on complications of peripherally inserted central catheter placement in patients with leukemia.

Authors:  Juan Wang; Xiaoli Xu
Journal:  Am J Transl Res       Date:  2022-05-15       Impact factor: 3.940

3.  Intensity-Modulated Radiotherapy and Three-Dimensional Conformal Radiotherapy Combined with Intracavitary Posterior Radiotherapy for the Treatment of Medium-Term and Advanced Cervical Cancer: Efficacy, Safety and Prognostic Factors.

Authors:  Kewen Yu; Liping Zhou
Journal:  Front Surg       Date:  2022-05-23

4.  Efficacy of Modified Qingre Jiedu Decoction Combined with Three-Dimensional Conformal Radiotherapy in Treating Moderate to Advanced Ovarian Carcinoma and Its Effect on Levels of Serum Carcinoembryonic Antigen and Carbohydrate Antigen 125.

Authors:  Shufen Ai; Jin Xie
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-15       Impact factor: 2.650

5.  Clinical experience of pelvic radiotherapy or chemoradiotherapy for postoperative uterine cervical cancer using intensity-modulated radiation therapy.

Authors:  Takaya Yamamoto; Rei Umezawa; Hideki Tokunaga; Masaki Kubozono; Maiko Kozumi; Noriyoshi Takahashi; Haruo Matsushita; Noriyuki Kadoya; Kengo Ito; Kiyokazu Sato; Keita Tsuji; Muneaki Shimada; Keiichi Jingu
Journal:  J Radiat Res       Date:  2020-05-22       Impact factor: 2.724

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.